Oche O Agbaji1, Maxwell O Akanbi2, Ihedinachi Otoh3, Patricia A Agaba4, Rolake Akinsola5, Victoria Okolie5, Placid O Ugoagwu3, Aliyu A Babadoko6, Adewumi Adediran7, Finomo O Finomo8, Jonah O Abah9, Haruna M Muktar6, Alani S Akanmu7. 1. Department of Medicine, University of Jos/Jos University Teaching Hospital; Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria. 2. Department of Medicine, University of Jos/Jos University Teaching Hospital; Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria; Health Sciences Integrated PhD Program, Center for Education in Health Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 3. Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria. 4. Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital; Department of Family Medicine, University of Jos/Jos University Teaching Hospital, Jos, Nigeria. 5. Department of Molecular Biology Research Laboratory, Lagos University Teaching Hospital, Lagos, Nigeria. 6. Department of Hematology, Ahmadu Bello University/Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. 7. Department of Hematology, College of Medicine, University of Lagos/Lagos University Teaching Hospital, Lagos, Nigeria. 8. Department of Medicine, Federal Medical Centre, Yenagoa, Nigeria. 9. Department of Family Medicine, Federal Medical Centre, Makurdi, Nigeria.
Abstract
Background: The presence of human leukocyte antigen (HLA) B*57:01 allele predicts hypersensitivity reaction (HSR) to abacavir (ABC), a nucleoside reverse-transcriptase inhibitor used for human immunodeficiency virus (HIV) treatment. However, the prevalence of this allele amongst Nigerians with HIV is yet to be established. We aimed to determine the prevalence of HLA-B*57:01 allele amongst Nigerians with HIV infection. Methods: We conducted a multicentre cross-sectional epidemiologic survey. Between April 2016 and April 2017, patients were enrolled across five HIV treatment facilities in Nigeria. Participants' demographic information and their history of ABC exposure were obtained, and venous blood was obtained for HLA typing. Results: One thousand five hundred and four (1504) adults were enrolled, with a mean age of 44.6 ± 10.7 years, 1078 (71.7%) were female. 1463 (97.3%) were on antiretroviral therapy. ABC use was reported by 12 (0.8%) participants and none reported HSR. Of 1500 blood samples that were processed, 1458 (97.2%) were successfully typed. Of these, 132 (9.1%) were HLA-B*57 positive using non-specific low-resolution HLA-B*5701 primer mix. On further analysis, none of the 132 samples (0%) had the HLA-B*5701 allele. Conclusion: HLA-B*5701allele is rare amongst Nigerians.
Background: The presence of human leukocyte antigen (HLA) B*57:01 allele predicts hypersensitivity reaction (HSR) to abacavir (ABC), a nucleoside reverse-transcriptase inhibitor used for human immunodeficiency virus (HIV) treatment. However, the prevalence of this allele amongst Nigerians with HIV is yet to be established. We aimed to determine the prevalence of HLA-B*57:01 allele amongst Nigerians with HIV infection. Methods: We conducted a multicentre cross-sectional epidemiologic survey. Between April 2016 and April 2017, patients were enrolled across five HIV treatment facilities in Nigeria. Participants' demographic information and their history of ABC exposure were obtained, and venous blood was obtained for HLA typing. Results: One thousand five hundred and four (1504) adults were enrolled, with a mean age of 44.6 ± 10.7 years, 1078 (71.7%) were female. 1463 (97.3%) were on antiretroviral therapy. ABC use was reported by 12 (0.8%) participants and none reported HSR. Of 1500 blood samples that were processed, 1458 (97.2%) were successfully typed. Of these, 132 (9.1%) were HLA-B*57 positive using non-specific low-resolution HLA-B*5701 primer mix. On further analysis, none of the 132 samples (0%) had the HLA-B*5701 allele. Conclusion:HLA-B*5701allele is rare amongst Nigerians.
Entities:
Keywords:
Abacavir; Africa; antiretroviral therapy; epidemiology; human immunodeficiency virus; hypersensitivity
Authors: S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen Journal: Lancet Date: 2002-03-02 Impact factor: 79.321
Authors: Paul J McLaren; Stephan Ripke; Kimberly Pelak; Amy C Weintrob; Nikolaos A Patsopoulos; Xiaoming Jia; Rachel L Erlich; Niall J Lennon; Carl M Kadie; David Heckerman; Namrata Gupta; David W Haas; Steven G Deeks; Florencia Pereyra; Bruce D Walker; Paul I W de Bakker Journal: Hum Mol Genet Date: 2012-06-19 Impact factor: 6.150
Authors: Edwin DeJesus; Gisela Herrera; Eugenio Teofilo; Jan Gerstoft; Carlos Beltran Buendia; J David Brand; Cynthia H Brothers; Jaime Hernandez; Steve A Castillo; Tab Bonny; E Randall Lanier; Trevor R Scott Journal: Clin Infect Dis Date: 2004-09-10 Impact factor: 9.079
Authors: Arlene R Hughes; Michael Mosteller; Aruna T Bansal; Kirstie Davies; Stephen A Haneline; Eric H Lai; Keith Nangle; Trevor Scott; William R Spreen; Liling L Warren; Allen D Roses Journal: Pharmacogenomics Date: 2004-03 Impact factor: 2.533
Authors: Amalia Rodriguez-French; Jack Boghossian; Glenda E Gray; Jeffrey P Nadler; Arnaldo R Quinones; Gladys E Sepulveda; Judith M Millard; Paul G Wannamaker Journal: J Acquir Immune Defic Syndr Date: 2004-01-01 Impact factor: 3.731
Authors: Wendy P Bannister; Nina Friis-Møller; Amanda Mocroft; Jean-Paul Viard; Jan van Lunzen; Ole Kirk; Panagiotis Gargalianos; Dénes Bánhegyi; Antonio Chiesi; Jens D Lundgren Journal: Antivir Ther Date: 2008
Authors: Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245
Authors: Paula Munderi; Wendy B Snowden; Ann Sarah Walker; Cissy Kityo; Michael Mosteller; Geoffrey Kabuye; Navdeep K Thoofer; Francis Ssali; Charles F Gilks; Arlene R Hughes Journal: Trop Med Int Health Date: 2010-11-23 Impact factor: 2.622